Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: Results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 238-242

  Schoels, M M ^a   Braun, J ^b   Dougados, M ^c   Emery, P ^d,e   Fitzgerald, O ^f   Kavanaugh, A ^g   Kvien, T K ^h   Landewe R ⁱ   Luger, T ^j   Mease, P ^k   Olivieri, I ^l   Reveille, J ^m   Ritchlin, C ⁿ   Rudwaleit, M ^o   Sieper, J ^o   Smolen, J S ^a   De Wit, M ^p   Van Der Heijde, D ^q  

^a HIETZING HOSPITAL   (Austria)

^b RHEUMAZENTRUM RUHRGEBIET   (Germany)

^c Hopital Cochin ^*  (France)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^f ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h DIAKONHJEMMET HOSPITAL   (Norway)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF MÜNSTER   (Germany)

^k UNIVERSITY OF WASHINGTON   (United States)

^l SAN CARLO HOSPITAL   (Italy)

^m UNIVERSITY OF TEXAS   (United States)

ⁿ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^o CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^p VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^q LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYCLOSPORIN A; GOLIMUMAB; INFLIXIMAB; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; SPONDYLARTHRITIS; VISUAL ANALOG SCALE;

ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS; SPONDYLOARTHRITIS; TREATMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; EVIDENCE-BASED MEDICINE; HUMANS; INTERNATIONALITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPONDYLARTHRITIS;

EID: 84889683977     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203860     Document Type: Article

References (43)

1. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
2. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
3. Smolen JS, Aletaha D, Bijlsma JW, et al. for the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
4. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
5. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6. (Pubitemid 39120376)
6. Smolen JS, Braun J, Dougados M, et al.; for the T2T Expert Committee. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Submitted for publication.
7. http://www.abstracts2view.com/eular/[Online]
8. http://www.rheumatology.org/publications/acr-arhp-annual-meeting.asp [Online]
9. http://www.clinicaltrials.gov [Online]
10. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43.
11. van der Heijde D, Kivitz A, Schiff MH, et al.; for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46. (Pubitemid 44051069)
12. Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91. (Pubitemid 40216323)
13. Inman RD, Davis JC, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
14. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58:1981-91. (Pubitemid 351988090)
15. Inman RD, Maksymowych WP; for the CANDLE Study Group. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 2010;37:1203-10.
16. Meric JC, Mulleman D, Ducourau E, et al. Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. Ther Drug Monit 2011;33:411-16.
17. Jois RN, Leeder J, Gibb A, et al. Low-dose infliximab treatment for ankylosing spondylitis-clinically- and cost-effective. Rheumatol (Oxford) 2006;45:1566-9. (Pubitemid 44817066)
18. Cherouvim EP, Zintzaras E, Boki KA, et al. Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3 mg/kg: a 20-month open treatment. J Clin Rheumatol 2004;10:162-8. (Pubitemid 39079592)
19. Collantes-Estevez E, Munoz-Villanueva MC, Zarco P, et al. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicenter study. Rheumatology (Oxford) 2005;44:1555-8. (Pubitemid 41742475)
20. Van Denderen JC, van der Horst-Bruinsma I, Bezemer PD, et al. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J Rheumatol 2003;30:1558-60. (Pubitemid 36835456)
21. Darmawan J, Nasution AR, Chen SL, et al. Excellent endpoints from step-down bridge combination therapy of 5 immunosuppressants in NSAID-refractory ankylosing spondylitis: 6 year international study in Asia - WHO-ILAR COPCORD stage II treatment of the autoimmune diseases. J Rheumatol 2006;33:2484-92. (Pubitemid 46067830)
22. Cheung PPM, Tymms KE, Wilson BJ, et al. Infliximab in severe active ankylosing spondylitis with spinal ankylosis. Intern Med J 2008;38:396-401. (Pubitemid 351871972)
23. Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008;58:88-97.
24. Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340-5. (Pubitemid 351281268)
25. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
26. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
27. Kavanaugh A, Krueger GG, Beutler A, et al.; for the IMPACT 2 Study Group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498-505. (Pubitemid 46580471)
28. Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004;63:156-61. (Pubitemid 38122134)
29. Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinical experience. J Rheumatol 1998;25:1957-61. (Pubitemid 28459310)
30. Simon P, Pfoehler C, Bergner R, et al. Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet. Clin Exp Rheumatol 2012;30:45-50.
31. Cresswell L, Chandran V, Farewell VT, et al. Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis 2011;70:305-8.
32. Bond SJ, Farewell VT, Schentag CT, et al. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 2007;66:370-6. (Pubitemid 46579640)
33. Brockbank JE, Stein M, Schentag CT, et al. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 2005;64:188-90. (Pubitemid 40193609)
34. Gladman DD, Mease PJ, Choy EH, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010;12:R113.
35. Kane D, Stafford L, Bresnihan B, et al. Prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatol (Oxford) 2003;42:1460-8. (Pubitemid 37508919)
36. Fitzgerald O, Chandran V. Update on biomarkers in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012;39:427-30.
37. De Jong EMGJ, Mork NJ, Seijger MMB, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 2003;148:318-25. (Pubitemid 36278975)
38. Beissert S, Pauser S, Sticherling M, et al. A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis. Dermatology 2009;219:126-32.
39. Nevin RJ, Schulz EJ. Treatement of psoriasis with cyclosporine. S Afr Med J 1995;85:1165-8.
40. Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009;23:1374-82.
41. Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
42. Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
43. Hannu T. Reactive arthritis. Best Pract Res Clin Rheum 2011;25:347-57.